article thumbnail

Health Transformation Alliance Teams up With Cognoa for Autism Diagnostic Device

MedCity News

Cognoa’s Canvas Dx product is authorized by the Food and Drug Administration and assists healthcare providers in diagnosing autism spectrum disorder for children ages 18 months through 72 months. Members of Health Transformation Alliance can now add Canvas Dx to their benefit plans.

article thumbnail

Can we get healthcare right?

World of DTC Marketing

Patients on Medicare who don’t qualify for low-income subsidies could see out-of-pocket costs for the drug of over $12,000. A bill to lower drug prices via negotiations with Medicare is finally moving forward, but PhRMA has bought some politicians. Information on public assistance and food stamps. Administration on Aging.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Disruption in healthcare is coming

World of DTC Marketing

America’s profit-riddled healthcare-industrial complex consumes 17% of GDP, equivalent to $3.6trn a year. However, changes are slowly being implemented that could lower healthcare costs. Healthcare is ripe for disruption, but any attempt to disrupt our state of healthcare has been met with pushback and challenges.

article thumbnail

FDA approves first-in-class oral antibiotic

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Blujepa ( gepotidacin ) antibiotic for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients aged 12 years old and over.

article thumbnail

4 Things That Worry FDA Commissioner Robert Califf

MedCity News

This week at HLTH, FDA Commissioner Robert Califf discussed the current state of healthcare AI. He talked about some of the qualms he has, such as his worry that AI is worsening health inequities and his concern that providers aren’t capable of validating AI tools’ effectiveness.

FDA 320
article thumbnail

Lilly has a new blockbuster

World of DTC Marketing

Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. The drug led to impressive blood sugar and body weight drops in clinical trials. Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks?

article thumbnail

Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval

Legacy MEDSearch

Food and Drug Administration (FDA) has approved the EMPAVELI Injector (enFuse ® ) for the subcutaneous delivery of EMPAVELI ® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. “Enable’s purpose is to redefine drug delivery for the benefit of patients. .